Salvia Jain

1.4k total citations
44 papers, 487 citations indexed

About

Salvia Jain is a scholar working on Oncology, Immunology and Pathology and Forensic Medicine. According to data from OpenAlex, Salvia Jain has authored 44 papers receiving a total of 487 indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Oncology, 21 papers in Immunology and 17 papers in Pathology and Forensic Medicine. Recurrent topics in Salvia Jain's work include Lymphoma Diagnosis and Treatment (17 papers), Cutaneous lymphoproliferative disorders research (12 papers) and T-cell and Retrovirus Studies (11 papers). Salvia Jain is often cited by papers focused on Lymphoma Diagnosis and Treatment (17 papers), Cutaneous lymphoproliferative disorders research (12 papers) and T-cell and Retrovirus Studies (11 papers). Salvia Jain collaborates with scholars based in United States, Italy and Australia. Salvia Jain's co-authors include Jasmine Zain, Owen A. O’Connor, O’Connor, Qinghu Ren, Liu C, Jonathan Harris, Catherine Diefenbach, Sherif Ibrahim, Jon Arnason and David Avigan and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Circulation Research.

In The Last Decade

Salvia Jain

41 papers receiving 484 citations

Peers

Salvia Jain
Shanta Chawla United States
Danielle Shafer United States
Justin Aubin United States
Joyce Lübbers Netherlands
Junfeng Chu China
Annalisa Roberti Spain
Elisa Ave Italy
Gökben Baskaynak Germany
L. Dousset France
Harald Biersack Germany
Shanta Chawla United States
Salvia Jain
Citations per year, relative to Salvia Jain Salvia Jain (= 1×) peers Shanta Chawla

Countries citing papers authored by Salvia Jain

Since Specialization
Citations

This map shows the geographic impact of Salvia Jain's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Salvia Jain with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Salvia Jain more than expected).

Fields of papers citing papers by Salvia Jain

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Salvia Jain. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Salvia Jain. The network helps show where Salvia Jain may publish in the future.

Co-authorship network of co-authors of Salvia Jain

This figure shows the co-authorship network connecting the top 25 collaborators of Salvia Jain. A scholar is included among the top collaborators of Salvia Jain based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Salvia Jain. Salvia Jain is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Iyer, Swaminathan P., Steven M. Horwitz, Salvia Jain, et al.. (2024). Confirmatory Efficacy and Safety Evaluation of MB-105, a CD5.CAR T Therapy: Multicenter Phase 2 Study in Patients with Relapsed/Refractory T Cell Lymphoma (R/R TCL). Blood. 144(Supplement 1). 7223–7223.
2.
Merrill, Mwanasha H., et al.. (2024). Real-World Evidence for Duvelisib and Romidepsin Combination in Patients with Relapsed/Refractory Peripheral T-Cell Lymphomas. Blood. 144(Supplement 1). 4453–4453. 2 indexed citations
3.
Horwitz, Steven M., Salvia Jain, Jacob D. Soumerai, et al.. (2024). Initial Results of a Phase 1 First-in-Human Study of Cemsidomide (CFT7455), a Novel MonoDACTM Degrader, in Patients with Non-Hodgkin's Lymphoma. Blood. 144(Supplement 1). 467–467. 4 indexed citations
4.
Dittus, Christopher, et al.. (2024). Mogamulizumab Combinations in Patients with Relapsing/Refractory Adult T-Cell Leukemia/Lymphoma (r/r ATLL). Blood. 144(Supplement 1). 6405–6405.
5.
Barnes, Jeffrey A., et al.. (2023). Prevalence of autoimmune diseases in cutaneous B-cell lymphoma: A retrospective cross sectional analysis. Journal of the American Academy of Dermatology. 90(1). 177–179.
6.
Jain, Salvia, Constantine S. Tam, Francesca Montanari, et al.. (2023). Real-world experience of combined treatment with azacitidine and romidepsin in patients with peripheral T-cell lymphoma. Blood Advances. 7(14). 3760–3763. 9 indexed citations
7.
8.
Asnani, Aarti, Javid J. Moslehi, Bishow B. Adhikari, et al.. (2021). Preclinical Models of Cancer Therapy–Associated Cardiovascular Toxicity: A Scientific Statement From the American Heart Association. Circulation Research. 129(1). e21–e34. 47 indexed citations
9.
Capelletti, Marzia, Dina Stroopinsky, Myrna Nahas, et al.. (2020). Development of Novel Second Generation DC/Tumor Fusion Vaccine in Lymphoma. Biology of Blood and Marrow Transplantation. 26(3). S316–S316. 3 indexed citations
10.
11.
Jain, Salvia, Abigail Washington, Rebecca Karp Leaf, et al.. (2017). Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Molecular Cancer Therapeutics. 16(10). 2304–2314. 10 indexed citations
12.
Bar‐Natan, Michal, Dina Stroopinsky, Katarina Luptakova, et al.. (2017). Bone marrow stroma protects myeloma cells from cytotoxic damage via induction of the oncoprotein MUC1. British Journal of Haematology. 176(6). 929–938. 23 indexed citations
13.
Jain, Salvia, Abigail Washington, Rebecca Karp Leaf, et al.. (2016). Decitabine Priming Enhances Mucin 1 Inhibition Mediated Disruption of Redox Homeostasis in Cutaneous T-Cell Lymphoma. Blood. 128(22). 4175–4175. 1 indexed citations
14.
Jain, Salvia, Kelly Zullo, Luigi Scotto, et al.. (2015). Preclinical Pharmacologic Evaluation of Pralatrexate and Romidepsin Confirms Potent Synergy of the Combination in a Murine Model of Human T-cell Lymphoma. Clinical Cancer Research. 21(9). 2096–2106. 49 indexed citations
15.
Jain, Salvia, Dina Stroopinsky, Yin Li, et al.. (2015). Mucin 1 is a potential therapeutic target in cutaneous T-cell lymphoma. Blood. 126(3). 354–362. 28 indexed citations
16.
Jain, Salvia, Jasmine Zain, & Owen A. O’Connor. (2012). Novel therapeutic agents for cutaneous T-Cell lymphoma. Journal of Hematology & Oncology. 5(1). 24–24. 39 indexed citations
17.
Harris, Jonathan, et al.. (2012). CD163 versus CD68 in tumor associated macrophages of classical hodgkin lymphoma. Diagnostic Pathology. 7(1). 12–12. 61 indexed citations
18.
Jain, Salvia, Carmine F. Palermo, Luigi Scotto, et al.. (2012). Novel Imaging Modalities in Innovative Xenograft Mouse Models of T-Cell Lymphoma Confirm Marked Synergy of Romidepsin and Pralatrexate.. Blood. 120(21). 2758–2758. 2 indexed citations
19.
Chen, Xiaowei, Diane Hamele‐Bena, Kar Fai Chow, et al.. (2011). B‐cell lymphoma of the vagina occurring after treatment for classic Hodgkin lymphoma: A case report and literature review. Diagnostic Cytopathology. 41(5). 463–465. 1 indexed citations
20.
Jain, Salvia, Catherine Diefenbach, Jasmine Zain, & O’Connor. (2011). Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. PubMed. 6. 43–43. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Shanta Chawla Breakdown of academic impact, for papers by Danielle Shafer Breakdown of academic impact, for papers by Justin Aubin Breakdown of academic impact, for papers by Joyce Lübbers Breakdown of academic impact, for papers by Junfeng Chu Breakdown of academic impact, for papers by Annalisa Roberti Breakdown of academic impact, for papers by Elisa Ave Breakdown of academic impact, for papers by Gökben Baskaynak Breakdown of academic impact, for papers by L. Dousset Breakdown of academic impact, for papers by Harald Biersack
Rankless by CCL
2026